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Dear Editor,
Bipolar disorder is associated with an increased risk of substance 
use disorders and hepatitis C virus (HCV) infection1. The prevalence 
of HCV in bipolar patients is 5 to 13-fold higher than in the general 
population, presenting a major clinical and therapeutic challenge2. 
We report a case of a patient with bipolar disorder, a history of heroin 
addiction, and HCV related cirrhosis with fatal outcome.
Case
Mr. A was a 44-year-old married white male, an artist, who was 
diagnosed with bipolar disorder in his late adolescence. He had 
recurrent manic or mixed psychotic episodes, effectively treated 
with antipsychotics and mood stabilizers. During a ten-year period 
of intravenous heroin misuse and dependency, he contracted HCV 
and subsequently developed liver cirrhosis. Induction of psychotic 
exacerbation hindered specific HCV infection treatment, which 
continued with hepatoprotectors and diuretics with poor adherence. 
The patient’s timeline is presented in Figure 1. 
The last psychiatric admission of Mr. A was at the age of 44. He 
presented with insomnia, elevated mood, megalomania, delusions, 
dysphoria, and lack of insight. Anaemia, thrombocytopenia, 
hypoalbuminemia, ascites and elevated transaminases were present. 
Zuclopenthixol resolved the psychiatric symptoms and the patient 
was referred to the hepatology department. A follow-up after one 
year was scheduled. The patient’s wife reported that he had died. He 
had been in stable mood following discharge and discontinued the 
psychiatric treatment. The improvement in the mental state improved 
the compliance with the somatic treatment and regimen, which led 
to temporary stabilization of the somatic state. However, his somatic 
condition deteriorated and he died from liver failure 3 months prior 
to the scheduled follow-up at the age of 45.
Discussion
Individuals with severe mental illness are estimated to die 
approximately 25 years earlier than the general population and up to 
60% of the premature deaths are due to general medical conditions3. 
Chronic HCV infection is a major concern, with an estimated 
infection rate up to 10–23.3% in bipolar patients as compared to 
1.8% in the general population4. The risk of liver cirrhosis is between 
15 and 30% within 20 years5 but risky social environment, high-
risk behaviors, and non-compliance can aggravate the condition in 
bipolar patients2.
New and highly effective therapies for chronic HCV infection are 
present, however access to treatment remains limited and psychiatric 
patients still suffer stigmatization6,7. Mental disorders were previously 
seen as contraindications against the use of interferon alfa and 
ribavirin in patients with chronic hepatitis C, as cases of mania and 
psychosis induced after initiation of treatment or upon withdrawal 
have been reported8,9. Current guidelines state that all HCV-infected 
patients should receive treatment, with patients with life-threatening 
conditions not expected to survive beyond 1 year being the only 
exclusion7. 
The case highlights the importance of an integrated model for 
clinical management of patients with comorbid HCV infection and 
bipolar disorder. An interdisciplinary approach and education of the 
patient are required in order to ensure the adequate treatment and 
compliance and prevent fatal outcomes10.
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Figure 1. History of the patient.
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